Stock Track | Teva Pharmaceutical Soars 5.41% in Pre-Market on Strong Q1 Earnings Beat and Emalex Acquisition

Stock Track

04/29

Teva Pharmaceutical Industries Ltd. (TEVA) surged 5.41% in pre-market trading on Wednesday, driven by the company's better-than-expected first-quarter 2026 financial results and the announcement of a strategic acquisition.

The pharmaceutical giant reported adjusted earnings per share of $0.53 for Q1 2026, surpassing analyst estimates of $0.48. Revenue reached $3.982 billion, exceeding expectations of $3.810 billion and representing a 2.34% increase year-over-year. The strong performance was attributed to growth in key innovative products including AUSTEDO, AJOVY, and UZEDY, which collectively grew by 41% year-over-year.

Additionally, Teva announced a definitive agreement to acquire Emalex Biosciences for $700 million, adding a first-in-class therapy for Tourette syndrome to its neuroscience pipeline. The company maintained its 2026 business outlook while updating it to reflect the Emalex transaction, demonstrating confidence in its continued growth trajectory under its "Pivot to Growth" strategy.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1190868944"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1190868944\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1190868944?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-29 19:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1190868944","market":"nz","top_or_hot":-1,"title":"Stock Track | Teva Pharmaceutical Soars 5.41% in Pre-Market on Strong Q1 Earnings Beat and Emalex Acquisition","media":"Stock Track","content":"<p>Teva Pharmaceutical Industries Ltd. (TEVA) surged 5.41% in pre-market trading on Wednesday, driven by the company's better-than-expected first-quarter 2026 financial results and the announcement of a strategic acquisition.</p><p>The pharmaceutical giant reported adjusted earnings per share of $0.53 for Q1 2026, surpassing analyst estimates of $0.48. Revenue reached $3.982 billion, exceeding expectations of $3.810 billion and representing a 2.34% increase year-over-year. The strong performance was attributed to growth in key innovative products including AUSTEDO, AJOVY, and UZEDY, which collectively grew by 41% year-over-year.</p><p>Additionally, Teva announced a definitive agreement to acquire Emalex Biosciences for $700 million, adding a first-in-class therapy for Tourette syndrome to its neuroscience pipeline. The company maintained its 2026 business outlook while updating it to reflect the Emalex transaction, demonstrating confidence in its continued growth trajectory under its \"Pivot to Growth\" strategy.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Teva Pharmaceutical Soars 5.41% in Pre-Market on Strong Q1 Earnings Beat and Emalex Acquisition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Teva Pharmaceutical Soars 5.41% in Pre-Market on Strong Q1 Earnings Beat and Emalex Acquisition\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-04-29 19:12</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Teva Pharmaceutical Industries Ltd. (TEVA) surged 5.41% in pre-market trading on Wednesday, driven by the company's better-than-expected first-quarter 2026 financial results and the announcement of a strategic acquisition.</p><p>The pharmaceutical giant reported adjusted earnings per share of $0.53 for Q1 2026, surpassing analyst estimates of $0.48. Revenue reached $3.982 billion, exceeding expectations of $3.810 billion and representing a 2.34% increase year-over-year. The strong performance was attributed to growth in key innovative products including AUSTEDO, AJOVY, and UZEDY, which collectively grew by 41% year-over-year.</p><p>Additionally, Teva announced a definitive agreement to acquire Emalex Biosciences for $700 million, adding a first-in-class therapy for Tourette syndrome to its neuroscience pipeline. The company maintained its 2026 business outlook while updating it to reflect the Emalex transaction, demonstrating confidence in its continued growth trajectory under its \"Pivot to Growth\" strategy.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEVA","symbol_name":"梯瓦製藥","start_time":0,"source_url":"","article_id":"1190868944","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1190868944","pubTimestamp":1777461164,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Teva Pharmaceutical Industries Ltd. (TEVA) surged 5.41% in pre-market trading on Wednesday, driven by the company's better-than-expected first-quarter 2026 financial results and the announcement of a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEVA":"梯瓦制药"},"translate_title":"个股追踪|梯瓦制药盘前大涨5.41%因Q1盈利强劲超预期及收购Emalex","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1},"content_text":"Teva Pharmaceutical Industries Ltd. (TEVA) surged 5.41% in pre-market trading on Wednesday, driven by the company's better-than-expected first-quarter 2026 financial results and the announcement of a strategic acquisition.The pharmaceutical giant reported adjusted earnings per share of $0.53 for Q1 2026, surpassing analyst estimates of $0.48. Revenue reached $3.982 billion, exceeding expectations of $3.810 billion and representing a 2.34% increase year-over-year. The strong performance was attributed to growth in key innovative products including AUSTEDO, AJOVY, and UZEDY, which collectively grew by 41% year-over-year.Additionally, Teva announced a definitive agreement to acquire Emalex Biosciences for $700 million, adding a first-in-class therapy for Tourette syndrome to its neuroscience pipeline. The company maintained its 2026 business outlook while updating it to reflect the Emalex transaction, demonstrating confidence in its continued growth trajectory under its \"Pivot to Growth\" strategy.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}